Literature DB >> 18951042

Optimal strategies for combining transcatheter arterial chemoembolization and radiofrequency ablation in rabbit VX2 hepatic tumors.

Elian M Mostafa1, Suvranu Ganguli, Salomao Faintuch, Pawel Mertyna, S Nahum Goldberg.   

Abstract

PURPOSE: To determine the optimum combination strategy of transcatheter arterial chemoembolization and radiofrequency (RF) ablation in an experimentally induced hepatic tumor model.
MATERIALS AND METHODS: Twenty-five New Zealand White rabbits with VX2 carcinoma-induced hepatic tumors were randomly divided into five treatment groups, which received (i) chemoembolization followed 15 minutes later by RF ablation; (ii) RF ablation followed by chemoembolization; (iii) chemoembolization alone; (iv) RF ablation alone; and (v) bland embolization followed by RF ablation. Animals were euthanized at 48 hours to determine tumor infarction and coagulation, which were compared with analysis of variance. Representative histopathologic slides were compared.
RESULTS: Significantly larger areas of coagulation were produced by chemoembolization followed by RF ablation (22.0 cm(3) +/- 7.7) compared with RF ablation followed by chemoembolization (13.1 cm(3) +/- 3.2) and RF ablation alone (10.0 cm(3) +/- 4.5; P < .05). RF ablation followed by chemoembolization showed larger treatment areas than chemoembolization alone (25.0 cm(3) +/- 9.6 vs 12.1 cm(3) +/- 4.6; P < .001), with chemotherapeutic agent preferentially depositing around the coagulation zone. Histopathologic analysis revealed greater vascular thrombosis and necrosis and reduced islands of viable tumor cells in the chemoembolization/RF ablation group versus the groups treated with chemoembolization alone or bland embolization/RF ablation.
CONCLUSIONS: Larger treatment volumes were produced when chemoembolization was performed before RF ablation than when RF ablation preceded chemoembolization or when RF ablation or chemoembolization were performed alone. Larger treatment volumes were also produced when chemoembolization rather than bland embolization was performed before RF ablation, indicating the importance and synergy of the chemotherapeutic regimen. These results suggest that the reduction of tumor blood flow combined with the effect of hyperthermia and local chemotherapy creates the largest dimensions of treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18951042     DOI: 10.1016/j.jvir.2008.08.028

Source DB:  PubMed          Journal:  J Vasc Interv Radiol        ISSN: 1051-0443            Impact factor:   3.464


  14 in total

Review 1.  Transcatheter embolization therapy in liver cancer: an update of clinical evidences.

Authors:  Yì-Xiáng J Wáng; Thierry De Baere; Jean-Marc Idée; Sébastien Ballet
Journal:  Chin J Cancer Res       Date:  2015-04       Impact factor: 5.087

2.  Development of a VX2 pancreatic cancer model in rabbits: a pilot study.

Authors:  Aaron C Eifler; Robert J Lewandowski; Sumeet Virmani; Johnathan C Chung; Dingxin Wang; Richard L Tang; Barbara Szolc-Kowalska; Gayle E Woloschak; Guang-Yu Yang; Robert K Ryu; Riad Salem; Andrew C Larson; Eric Cheon; Matthew Strouch; David J Bentrem; Reed A Omary
Journal:  J Vasc Interv Radiol       Date:  2009-06-28       Impact factor: 3.464

Review 3.  Novel approaches to treatment of hepatocellular carcinoma and hepatic metastases using thermal ablation and thermosensitive liposomes.

Authors:  Mark W Dewhirst; Chelsea D Landon; Christina L Hofmann; Paul R Stauffer
Journal:  Surg Oncol Clin N Am       Date:  2013-03-13       Impact factor: 3.495

Review 4.  Technical and practical considerations for device selection in locoregional ablative therapy.

Authors:  Sean P Zivin; Ron C Gaba
Journal:  Semin Intervent Radiol       Date:  2014-06       Impact factor: 1.513

5.  Imaging Intratumoral Nanoparticle Uptake After Combining Nanoembolization with Various Ablative Therapies in Hepatic VX2 Rabbit Tumors.

Authors:  Alda L Tam; Marites P Melancon; Mohamed Abdelsalam; Tomas Appleton Figueira; Katherine Dixon; Amanda McWatters; Min Zhou; Qian Huang; Osama Mawlawi; Kenneth Dunner; Chun Li; Sanjay Gupta
Journal:  J Biomed Nanotechnol       Date:  2016-02       Impact factor: 4.099

Review 6.  Ablation plus Transarterial Embolic Therapy for Hepatocellular Carcinoma Larger than 3 cm: Science, Evidence, and Future Directions.

Authors:  Andrew R Lewis; Carlos A Padula; J Mark McKinney; Beau B Toskich
Journal:  Semin Intervent Radiol       Date:  2019-10-31       Impact factor: 1.513

7.  Combination radiofrequency ablation and intravenous radiolabeled liposomal Doxorubicin: imaging and quantification of increased drug delivery to tumors.

Authors:  Hayden W Head; Gerald D Dodd; Ande Bao; Anuradha Soundararajan; Xavier Garcia-Rojas; Thomas J Prihoda; Linda M McManus; Beth A Goins; Cristina A Santoyo; William T Phillips
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

8.  Evaluation of the Heat Sink Effect After Transarterial Embolization When Performed in Combination with Thermal Ablation of the Liver in a Rabbit Model.

Authors:  Charles J Puza; Qi Wang; Charles Y Kim
Journal:  Cardiovasc Intervent Radiol       Date:  2018-07-23       Impact factor: 2.740

Review 9.  Combining locoregional therapies in the treatment of hepatocellular carcinoma.

Authors:  Mikhail C S S Higgins; Michael C Soulen
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

10.  Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.

Authors:  Daniel Coman; Julius Chapiro; Lynn Jeanette Savic; Isabel Theresa Schobert; Dana Peters; John J Walsh; Fabian Max Laage-Gaupp; Charlie Alexander Hamm; Nina Tritz; Luzie A Doemel; MingDe Lin; Albert Sinusas; Todd Schlachter; James S Duncan; Fahmeed Hyder
Journal:  Clin Cancer Res       Date:  2019-10-03       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.